10-KPeriod: FY2025

PFIZER INC Annual Report, Year Ended Dec 31, 2025

Filed February 26, 2026For Securities:PFE

Summary

Pfizer Inc.'s 2025 10-K filing reveals a company navigating a dynamic landscape, with total revenues experiencing a slight 2% decrease to $62.6 billion, primarily due to a significant decline in COVID-19 product revenues (Comirnaty and Paxlovid). Excluding these products, the company saw a 6% operational revenue increase, driven by strong performance in its Vyndaqel family, Eliquis, Padcev, and oncology portfolio. The company is strategically focused on maximizing value from key transactions, delivering on R&D milestones, investing for post-2028 growth, and scaling AI across its business. Pfizer continues to manage significant patent expirations, anticipating a substantial reduction in revenue from these events between 2026 and 2030, with an expected impact of $1.5 billion in 2026. The company is also actively managing pricing pressures and regulatory changes, including the impact of the IRA and the U.S. government's Most-Favored-Nation initiatives. Significant investments in business development, such as the acquisitions of Seagen and Metsera, underscore Pfizer's commitment to strengthening its pipeline, particularly in oncology and obesity. Despite revenue headwinds from COVID-19 products and upcoming patent cliffs, Pfizer's diversified portfolio, ongoing R&D investments, and strategic business development initiatives position it to address unmet medical needs and drive future growth. Investors will be closely watching the company's ability to execute on its strategic priorities, manage patent expirations, and adapt to the evolving regulatory and pricing environment.

Financial Highlights

54 data points
Beta

Revenue

$62.58B

74.3% Gross Margin

Net Income

$7.77B

12.4% Net Margin

EPS (Diluted)

$1.36

Total Assets

$208.16B

Cash & Equivalents

$1.14B

Free Cash Flow

$9.07B

Financial Statements
Beta
Revenue$62.58B
Cost of Revenue$16.07B
Gross Profit$46.51B
SG&A Expenses$13.79B
Interest Expense$2.67B
Net Income$7.77B
EPS (Basic)$1.37
EPS (Diluted)$1.36
Shares Outstanding (Basic)5.68B
Shares Outstanding (Diluted)5.71B

Key Highlights

  • 1Total revenues decreased 2% to $62.6 billion in 2025, primarily driven by lower COVID-19 product revenues (Comirnaty and Paxlovid).
  • 2Excluding COVID-19 products, total revenues increased 6% operationally, fueled by strong performance in the Vyndaqel family, Eliquis, Padcev, and other oncology products.
  • 3Pfizer anticipates a significant reduction in revenue from patent and regulatory exclusivity expiries between 2026 and 2030, with an estimated impact of $1.5 billion in 2026.
  • 4The company's key priorities for 2026 include maximizing value from key transactions, delivering on critical R&D milestones, investing for post-2028 growth, and scaling AI across the business.
  • 5Major acquisitions in 2025 include Metsera (obesity/cardiometabolic) and the ongoing integration of Seagen (oncology) from 2023, indicating strategic focus on these therapeutic areas.
  • 6The company is actively managing pricing pressures and regulatory changes, including impacts from the Inflation Reduction Act (IRA) and the 'Most-Favored-Nation' pricing initiatives.
  • 7Despite the revenue challenges, Pfizer's R&D pipeline remains a key focus, with ongoing investments to develop new therapies.

Frequently Asked Questions

Pfizer experienced a 2% overall revenue decline in 2025, primarily due to a significant drop in sales of Comirnaty and Paxlovid. However, the company's core biopharmaceutical business, excluding these COVID-19 products, showed operational growth of 6%. This growth was driven by strong demand and market uptake for key products like the Vyndaqel family, Eliquis, Padcev, and several oncology products. Pfizer expects this growth to continue, offsetting the decline in COVID-19 related revenues.

Pfizer acknowledges the significant impact of patent expirations and regulatory exclusivity losses on its revenue. The company anticipates a substantial revenue reduction between 2026 and 2030, with an estimated impact of $1.5 billion in 2026. To mitigate this, Pfizer is focusing on advancing its product pipeline through internal R&D and strategic business development activities, such as the acquisitions of Seagen and Metsera, to fill the revenue gap and drive future growth.

Pfizer has outlined four key strategic priorities for 2026: 1) Maximize value of key transactions, referring to the integration of recent acquisitions and ongoing business development. 2) Deliver on critical R&D milestones, highlighting the importance of its pipeline. 3) Invest to maximize post-2028 growth, indicating a long-term view on innovation. 4) Scale AI across its business, aiming to enhance productivity and accelerate innovation throughout its operations.

Pfizer is actively engaged in managing pricing pressures and navigating a complex regulatory environment. This includes addressing the impact of the Inflation Reduction Act (IRA), which has led to changes in Medicare Part D benefits and the introduction of maximum fair pricing for certain drugs like Eliquis, Ibrance, Xtandi, and Xeljanz. The company is also responding to government initiatives like the 'Most-Favored-Nation' pricing proposals. Pfizer emphasizes its commitment to demonstrating the value of its products and engaging with policymakers to ensure patient access to medicines.